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Abstract
PhIP carcinogenesis is initiated by N2-hydroxylation, mediated by several cytochromes 
P450, including CYP1A1. However, the role of CYP1A1 in PhIP metabolic activation in 
vivo is unclear. In this study, Cyp1a1-null and wild-type (WT) mice were used to 
investigate the potential role of CYP1A1 in PhIP metabolic activation in vivo. PhIP N2-
hydroxylation was actively catalyzed by lung homogenates of WT mice, at a rate of 14.9 
± 5.0 pmol/min/g tissue, but < 1 pmol/min/g tissue in stomach and small intestine, and 
almost undetectable in mammary gland and colon. PhIP N2-hydroxylation catalyzed by 
lung homogenates of Cyp1a1-null mice was ~10-fold lower than that of WT mice. In 
contrast, PhIP N2-hydroxylation activity in lung homogenates of Cyp1a2-null versus WT 
mice was not decreased. Pretreatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
increased lung Cyp1a1 mRNA and lung homogenate PhIP N2-hydroxylase activity ~50-
fold in WT mice, where the activity was substantially inhibited (70%) by monoclonal 
antibodies against CYP1A1. In vivo, 30 min after oral treatment with PhIP, PhIP levels in 
lung were similar to those in liver. After a single dose of 0.1 mg/kg [14C]PhIP, lung PhIP-
DNA adduct levels in Cyp1a1-null mice, but not in Cyp1a2-null mice, were significantly 
lower (P=0.0028) than in WT mice. These results reveal that mouse lung has basal and 
inducible PhIP N2-hydroxylase activity predominantly catalyzed by CYP1A1. Because of 
the high inducibility of human CYP1A1, especially in cigarette smokers, the role of lung 
CYP1A1 in PhIP carcinogenesis should be considered. (237 words).
Introduction
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), the most abundant dietary 
heterocyclic amine, is carcinogenic in multiple organs and in numerous species. PhIP 
carcinogenesis is initiated by PhIP N2-hydroxylation [1], which has been reported to be 
primarily catalyzed by CYP1A2 [2-4]. However, recent studies raise the possibility of the 
CYP1A2-independent pathways for PhIP metabolic activation. In humans, excretion of 
the glucuronide conjugate of N2-hydroxy PhIP (N-OH-PhIP) in urine shows a low 
correlation with CYP1A2 activity [5]. In a mouse carcinogen bioassay with PhIP, the 
incidence of lymphomas and hepatocellular adenomas is higher in Cyp1a2-null mice than 
WT mice [6]. Moreover, PhIP-DNA adducts are detectable in mammary gland and colon 
in Cyp1a2-null mice [7].
Multiple in vitro studies have revealed that CYP1A1 catalyzes PhIP metabolic activation 
[8-11]. cDNA-expressed human CYP1A2, CYP1A1 and CYP1B1, respectively catalyze 
N-OH-PhIP formation with maximal velocities (Vmax) of 90, 16 and 0.2 nmol/min/nmol 
P450, and apparent Km values of 79, 5.1 and 4.5 μM [12]. Thus, although CYP1A2 
exhibited the highest Vmax for N-OH-PhIP production, the catalytic efficiency 
(Vmax/Km) of CYP1A1 is 2.75-fold higher than that of CYP1A2. With CYP1B1, PhIP 
N2- hydroxylation activity is 80-fold lower than that of CYP1A1 and formation of the 
nonmutagenic metabolite 4-OH PhIP is favored ~2-fold over that of the promutagenic 
metabolite N-OH-PhIP [12,13]. Given the high catalytic efficiency of CYP1A1 for PhIP 
metabolic activation, it is important to establish the potential role of extrahepatic 
CYP1A1 in PhIP metabolism and carcinogenesis. Such studies are particularly important 
because PhIP induces tumors in several extrahepatic organs. In the current study, PhIP 
N2-hydroxylase activity was detected in extrahepatic organs including lung, stomach, 
small intestine, colon, and mammary gland. Cyp1a2-null mice were used to examine 
CYP1A2-independent PhIP metabolic pathways and Cyp1a1-null mice were used to 
assess the potential role of CYP1A1 in PhIP metabolic activation.
Materials and Methods
Chemicals and reagents
PhIP and N-OH-PhIP were obtained from the National Cancer Institute Chemical 
Carcinogen Reference Standard Repository at the Midwest Research Institute (Kansas 
City, MO). [14C]PhIP, > 95% radio-pure, was purchased from Toronto Research 
Chemicals Inc. (Ontario, Canada). 4'-Hydroxy-PhIP (4-OH-PhIP) was provided by Dr. 
M. Nagao (National Cancer Research Center, Tokyo, Japan). NADPH and 6-
chloromelatonin were purchased from Sigma-Aldrich (St. Louis, MO). Monoclonal 
antibodies against CYP1A1 (mAb 1-7-1) were used to study CYP1A1 inhibition [14,15]. 
High-performance liquid chromatography solvents and other chemicals were of the 
highest grade commercially available. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) was 
obtained from Dr. Steven Safe at Texas A&M University.
Animals and treatments
Cyp1a1-null mice [16], Cyp1a2-null mice [17], and their corresponding wild-type (WT) 
mice, female, 2-4 months old, were maintained under a standard 12 h light/12 h dark 
cycle with water and chow provided ad libitum. Handling was in accordance with animal 
study protocols approved by the National Cancer Institute Animal Care and Use 
Committee. For CYP1A1 induction, WT and Cyp1a1-null mice were injected i.p. with 10 
μg/kg TCDD and sacrificed 72 h after dosing. TheTCDD dose and time was chosen were 
based on earlier published studies showing maximal induction of CYP1A1 [18]. For the 
in vivo PhIP distribution, WT mice were treated by oral gavage with 40 mg/kg PhIP. 30 
min after PhIP treatment, mice were killed by CO2 asphyxiation; lung, liver, mammary 
gland and colon were collected and frozen at -80 °C for further analysis. For PhIP-DNA 
adducts detection, Cyp1a1-null mice, Cyp1a2-null mice, and WT mice were treated 
orally with 100 μg/kg of [14C]PhIP (6.3 μCi/kg). The mice were sacrificed 18 h after 
administration, and tissues were collected and frozen at -80 °C for further analysis.
PhIP metabolism in extrahepatic organs
PhIP metabolism in extrahepatic organs was detected in vitro using tissue homogenates. 
To prepare homogenates, each organ was washed with 20 mM phosphate-buffered saline 
(PBS), pH 7.4, and homogenized (500 μl PBS/100 mg tissue) by a motor-driven Teflon 
tipped pestle. PhIP metabolism in homogenates (20 mg tissue) were assayed in a final 
volume of 400 μl, containing 20 mM PBS, pH 7.4, 10 μM PhIP and 1 mM NADPH. To 
assess the role of CYP1A1 in PhIP metabolism, monoclonal antibodies against CYP1A1 
(mAb 1-7-1) were pre-incubated for 5 min with lung homogenates at 37 °C. Reactions 
were initiated by the addition of NADPH and terminated 10 min later by the addition of 
1.0 ml ethyl acetate and 1.0 ml methyl tert-butyl ether. 6-Chloromelatonin (5 μl of 100 
μM stock solution) was added as an internal standard. Samples were centrifuged at 3000 
rpm for 5 min at 4 °C. The organic layer was then transferred to a new tube, dried with 
N2 and reconstituted in 100 μl of 70% methanol and 30% H2O containing 0.1% formic 
acid. All reactions were performed in duplicate. PhIP metabolites were detected by LC-
MS/MS.
PhIP tissue distribution
PhIP in various tissues was extracted 30 min after a single oral dose of PhIP administered 
to WT mice. Briefly, 100 mg of each tissue was homogenized in 500 μl PBS, and 300 μl 
of each homogenate was extracted with a mixture of 1.0 ml ethyl acetate and 1.0 ml 
methyl tert-butyl ether. 6-Chloromelatonin (5 μl of 100 μM solution) was added as an 
internal standard. The extracted samples were dried with N2 and reconstituted in 100 μl of 
70% methanol and 30% H2O containing 0.1% formic acid. 6 μl of each sample was used 
for LC-MS/MS analysis.
Identification and quantification of PhIP and PhIP metabolites by LC-MS/MS
PhIP metabolites were detected by LC-MS/MS, as described previously [4]. Briefly, 
LCMS/MS analysis was performed using a PE SCIEX API 2000 ESI triple quadrupole 
mass spectrometer (PerkinElmer/ABI, Foster City, CA). A Luna C18 50 mm x 4.6 mm 
i.d. column (Phenomenex, Torrance, CA) was used to separate PhIP metabolites. The 
flow rate through the column at ambient temperature was 0.25 ml/min with 70% 
methanol and 30% H2O containing 0.1% formic acid. The mass spectrometer was 
equipped with a turbo ion spray source and run in the positive ion mode. The turbo ion 
spray temperature was maintained at 350 °C and a voltage of 4.8 kV was applied to the 
sprayer needle. N2 was used as the turbo ion spray and nebulizing gas. Identification and 
quantification of PhIP metabolites and the internal standard were accomplished by 
multiple reactions monitoring (MRM) with the transitions m/z 225.2/210.2 for PhIP, 
241.2/223.2 for N-OH-PhIP, 241.2/226.2 for 4-OH-PhIP, and 267.0/208.4 for 6-
Chloromelatonin.
Lung Cyp1a1 mRNA detection
Relative levels of mouse lung Cyp1a1 RNA were quantified by real time quantitative 
PCR (qPCR) using SYBR Green I chemistry. Total RNA was isolated from individual 
mouse lung samples obtained from untreated and TCDD-treated WT and Cyp1a1-null 
mice, using Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA) and the 
manufacturer’s protocol for tissue. The isolated RNA was treated with ribonuclease-free 
deoxyribonuclease followed by reverse transcription using random hexamers and murine 
leukemia virus reverse transcriptase to yield cDNA using the GeneAmp RNA core kit 
(Applied Biosystems, Foster City, CA). One μg of total lung RNA was converted to 
cDNA in a final vol of 20 μl according to the manufacturer’s protocol. Triplicate samples 
of each qPCR mixture, each containing 4 μl of SYBR Green I PCR master mix (Applied 
Biosystems), were transferred into separate wells of a 384-well plate and run through 40 
cycles on an ABS 7900HT Sequence Detection System (Applied Biosystems) [19].
Samples were initially incubated at 95° C for 10 min, followed by 40 cycles of 95oC for 
15 s and 60°C for 1 min. Dissociation curves were generated after each qPCR run to 
ensure that a single, specific product was amplified. Results were analyzed using the 
comparative CT (ΔΔCT) method, as described in User Bulletin 2 of the ABI PRISM 7700 
Sequence Detection System. Data are graphed as relative RNA values, normalized to the 
18S rRNA content of each sample. Similar results were obtained by normalization to β-
actin RNA (data not shown). qPCR primers for Cyp1a1 were as follows: forward primer 
ON-1582 (5’-GGT TAA CCA TGA CCG GGA ACT-3’) and reverse primer ON-1583 
(5’-TGC CCA AAC CAA AGA GAG TGA), yielding an amplicon length of 122 
nucleotides. The forward primer was designed to span the junction between exons 6 and 
7 of the mouse Cyp1a1 gene (NM_009992) to eliminate amplification of any 
contaminating genomic DNA. Primers for β-actin (forward primer 5’-TCC ATC ATG 
AAG TGT GAC GTT-3’; reverse primer 5’-TGT GTT GGC ATA GAG GTC TTT 
ACG-3’) and 18S rRNA (forward primer 5’-CGC CGC TAG AGG TGA AA TC-3’; 
reverse primer 5’-CCA GTC GGC ATC GTT TAT GG-3’) were as shown. Primer 
specificity was verified by BLAST analysis.
Lung PhIP-DNA adduct detection
DNA isolation from mouse lung, and sample preparation for the quantification of DNA 
adduct levels by accelerator mass spectrometry (AMS) has been reported elsewhere [20]. 
Briefly, lung tissues were homogenized then digested in lysis buffer (4 M urea, 1.0% 
Triton X-100, 10 mM EDTA, 100 mM NaCl 10 mM DTT, 10 mM Tris-HCl, pH 8.0) 
containing 0.8 mg/ml proteinase K overnight at 37 °C. Undigested tissue was removed by 
centrifugation, and the supernatant was treated for 1 h at room temperature with RNase 
A, (0.5 mg/ml) and RNase T1 (5 μg/ml). DNA was extracted using Qiagen column 
chromatography (Qiagen, Valencia, CA) according to the manufacturer’s instructions. 
DNA purity was determined by the A260 nm/A280 nm ratio. A ratio between 1.6-1.8 was 
considered pure. Pure DNA samples were then submitted for adduct analysis by AMS.
Statistical analysis
All values are expressed as the means ± SD and analyzed by Student's t test. P<0.05 was 
regarded as significantly different between the compared groups.
Results
PhIP metabolism in extrahepatic organs
Extrahepatic PhIP metabolism was investigated using tissue homogenates prepared from 
WT mouse lung, stomach, small intestine, colon and mammary gland. The velocity of 
PhIP N2-hydroxylation was highest in the lung, 14.9 ± 5.0 pmol/min/g tissue, whereas it 
was below 1 pmol/min/g tissue in stomach and small intestine, and almost undetectable in 
mammary gland and colon (Figure 1A). PhIP 4'-hydroxylation, a non-mutagenic 
metabolic pathway, exhibited similar tissue specificity. PhIP N2-hydroxylation in lung is 
NADPH- and enzyme(s)-dependent, as N-OH-PhIP was not detected in the absence of 
NADPH or tissue homogenate (Figure 1B).
PhIP metabolism in lung is CYP1A1-dependent
PhIP metabolism was assayed in lung homogenates prepared from Cyp1a1-null mice, 
Cyp1a2-null mice, and WT mice. There was a marked decrease in PhIP N2-hydroxylation 
and 4'-hydroxylation activities in Cyp1a1-null mouse lung homogenates (Figure 2B) 
compared to WT mice (Figure 2A). The ~10-fold lower PhIP N2-hydroxylase activity in 
Cyp1a1-null mouse lung homogenates contrasts with a ~50% higher PhIP N2-
hydroxylase activity in Cyp1a2-null mouse lung homogenates (Figure 2C). The increase 
of PhIP N2-hydroxylase activity in Cyp1a2-null mouse lung homogenates can be 
significant inhibited (~90%) by monoclonal antibody (mAb) against CYP1A1. These 
data indicate that PhIP hydroxylation activity in lung is largely mediated by CYP1A1, 
rather than CYP1A2.
Effect of CYP1 inducer on PhIP hydroxylase activity in lung
In lung homogenates of WT mice pretreated with the CYP1 inducer TCDD, PhIP N2-
hydroxylase activity was increased ~50-fold, to 636 ± 167 pmol/min/g tissue, compared 
to untreated WT controls (Figure 3A). Similar results were obtained for PhIP 4'-
hydroxylation. PhIP N2-hydroxylation in lung homogenates of TCDD-treated Cyp1a1-
null mice was ~80% lower than that of TCDD-treated WT mice (Figure 3B). Monoclonal 
antibody (mAb) against CYP1A1 inhibited PhIP N2-hydroxylation in WT lung by ~70%, 
but had no significant effect on that of Cyp1a1-null mice (Figure 3B). Consistent with the 
activity increase, lung Cyp1a1 mRNA was increased ~50-fold in WT mice after TCDD 
treatment. Moreover, Cyp1a1 mRNA was readily detectable in untreated WT mouse lung 
at ~ 2-2.5% the level of TCDD-treated WT mouse lung (Figure 4). While CYP1A1 
protein was readily detected in TCDD-treated mouse lung, the protein was not detected in 
untreated mouse lung tissues, even though PhIP N2-hydroxylation activity was readily 
detected. This is due to the limited sensitivity of western blotting compared to the high 
sensitivity of the LC-MS for detection of the N2-hydroxy metabolite of PhIP.
PhIP distribution in mouse lung
30 min after oral PhIP treatment (40 mg/kg), mouse lung, liver, mammary gland and 
colon tissue were collected, and PhIP distribution was assayed by LC-MS/MS. Liver had 
the highest PhIP concentration at 46.4 nmol/g tissue (Figure 5). Interestingly, lung had 
similar PhIP level as liver (41.9 nmol/g tissue). PhIP concentration in mammary gland 
and colon was lower than that of liver and lung (22.1 and 29.4 nmol/g tissue, 
respectively). The high level of PhIP in lung raises the possibility of localized PhIP 
metabolic activation by lung CYP1A1. There was no significant difference in PhIP tissue 
distribution between WT, Cyp1a1-null, and Cyp1a2-null mice (data not shown).
PhIP-DNA adducts in lung
PhIP-DNA adducts in lung of Cyp1a1-null mice, Cyp1a2-null mice, and WT mice were 
analyzed after a single dose of 100 μg/kg [14C]PhIP (6.3 μCi/kg). PhIP-DNA adducts 
were detected by accelerator mass spectrometry (AMS). PhIP-DNA adducts were 
significantly lower (46%) in Cyp1a1-null mouse lung than that in WT mouse lung 
(P=0.0028). In contrast, there was no significant change in PhIP-DNA adduct levels in 
Cyp1a2-null lung (P=0.177) (Figure 6).
Discussion
PhIP N2-hydroxylation is considered as the initiating step in PhIP carcinogenesis [1]. 
Previous studies showed PhIP metabolic activation by lung microsomes, using 
mutagenicity as an endpoint [21]. In the present study using Cyp1a1-null versus Cyp1a2-
null mice, PhIP N2-hydroxylase activity in lung was shown to be CYP1A1-dependent. 
Expression of CYP1A1 in human lung has been well characterized [22,23]; a 
centrilobular expression of CYP1A1 mRNA and CYP1A protein was observed in 
peripheral lung [24]. Both constitutive and inducible lung CYP1A1 have been quantified, 
and the median levels of CYP1A1 were 15.5 pmol/mg microsomal protein in smokers, 
6.0 pmol/mg microsomal protein in nonsmokers, and 19.0 pmol/mg microsomal protein 
in ex-smokers [25]. Lung CYP1A1 activity is increased ~100-fold in smokers as 
compared with that of nonsmokers [26,27]. In the current study, lung CYP1A1 
expression and PhIP N2-hydroxylase activity were readily detectable in untreated WT 
mice. After TCDD treatment, lung CYP1A1 RNA and PhIP N2-hydroxylase activity were 
both markedly induced. These results raise the possibility of localized CYP1A1-mediated 
PhIP metabolic activation in lung that is of importance due to different routes of PhIP 
exposure to lung. The diet is considered the most common source of PhIP, and orally 
administered PhIP has been shown to localized in lung [28]. In the present study with oral 
PhIP treatment, lung had a PhIP concentration similar to that in liver. Besides oral 
exposure, inhalation is another important pathway for PhIP exposure to the lung. PhIP is 
detected in all brands of filter-tipped cigarettes, and the mean level of PhIP in cigarette 
mainstream smoke has been estimated at 16.4 ng/cigarette [29]. PhIP is also detected in 
airborne particles, diesel-exhaust particles, and incineration ash from garbage-burning 
plants [30]. PhIP-DNA adduct is considered a reliable biomarker for PhIP exposure, and 
it has been detected in lung in several previous studies. In monkeys after a single oral 
dose of PhIP, DNA adducts were highest in the liver followed by the lung [31]. PhIP-
DNA adducts in mouse lung has also been reported, and these levels were significantly 
decreased by inhibiting the activity of CYP1A1 and CYP1A2 [32]. In the present study, 
lung PhIP-DNA adducts were significant lower in lung tissue of Cyp1a1-null mice, but 
not Cyp1a2-null mice, compared to WT mice, which highlights the importance of 
CYP1A1 in PhIP metabolic action in lung. These data also demonstrate the utility of 
comparing various knockout mouse lines instead of relying on CYP inhibitor studies 
[33]. Compared to the in vitro data supporting a role for lung CYP1A1 (~90%) in PhIP 
N2-hydroxylation, the apparent contribution of CYP1A1 (~50%) to PhIP-DNA adduct 
formation is not particularly dominant. Perhaps other factors or enzymes may also 
contribute to the formation of PhIP-DNA adducts, including N-acetyltransferases, prolyl-
tRNA synthetases, phosphorylases, sulfotransferases, UDPglucuronyltransferase, and 
enzymes involved in DNA repair [34,35].
Lung cancer is the leading cause of death among women worldwide, and cigarette 
smoking and second-hand smoking are regarded as the predominant risk factor [36-38]. 
However, lung cancer also strikes women absent from smoking [39]. For example, 
Chinese women have a high incidence of lung cancer despite a low smoking prevalence, 
and domestic exposure to cooking fumes is proposed as an important risk factor [40]. 
Associations between Chinese-style cooking and lung cancer has been confirmed in 
several epidemiological investigations [41-44]. Procarcinogens, including PhIP and 2-
amino-3,8- dimethylimidazo[4,5-f]quinoxaline (MeIQx), were identified in smoke 
condensates from the frying meat [45]. In the present study, localized procarcinogen 
metabolic activation by CYP1A1 in mouse lung has been demonstrated which may be an 
important risk factor for occupationally relevant human lung cancer. Because of the high 
efficiency of CYP1A1 in PhIP N2-hydroxylation and high inducibility of human 
CYP1A1, especially in smokers, the role of lung CYP1A1 in PhIP carcinogenesis should 
be considered.
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Figure legends
Fig. 1. PhIP hydroxylase activity in extrahepatic organs of WT mice. (A) PhIP 
hydroxylase activity in homogenates of lung, small intestine, stomach, mammary gland 
an colon. (B) Relative PhIP hydroxylase activity in lung homogenates. The incubations 
were carried out with or without homogenates (20 mg tissue) and/or 1 mM NADPH. 
PhIP metabolites were detected by LC-MS/MS. Data are expressed as means ± SD (n=3).
Fig. 2. PhIP metabolism in lung homogenates. (A) Typical chromatography of PhIP 
metabolites in lung homogenates of WT mice. (B) Typical chromatography of PhIP 
metabolites in lung homogenates of Cyp1a1-null mice. PhIP metabolites were detected 
by LC-MS/MS, 241.2/226.2 for 4-OH-PhIP (1), 241.2/223.2 for N-OH-PhIP (2), and 
267.0/208.4 for 6-Chloromelatonin (3, as an internal standard). (C) Relative 
quantification of PhIP N2-hydroxylase activity in lung homogenates of Cyp1a1-null mice 
and Cyp1a2-null mice. PhIP N2-hydroxylase activity in WT mouse lung homogenates 
was set as 1.0. Data are expressed as means ± SD (n=3). **P<0.01 and *P<0.05 
compared with WT mice.
Fig. 3. PhIP hydroxylase activity in lung homogenates of WT versus Cyp1a1-null mice, 
with or without TCDD pretreatment. (A) Comparison of PhIP hydroxylase activity in 
lung homogenates of untreated versus TCDD-treated WT mice. Data are expressed as 
means ± SD (n=3). **P<0.01 compared with that of untreated WT mice. (B) Comparison 
of PhIP N2-hydroxylase activity in lung homogenates of TCDD-treated WT versus 
Cyp1a1-null mice. PhIP N2-hydroxylase activity in WT lung homogenates without 
monoclonal antibodies (mAb) against CYP1A1 was set as 1.0. Data are expressed as
means ± SD (n=3). **P<0.01 compared to that of WT without mAb.
Fig. 4. Relative levels of lung Cyp1a1 mRNA in untreated and TCDD-treated WT and 
Cyp1a1-null mice. Lung Cyp1a1 RNA was quantified by real time quantitative PCR 
(qPCR) using SYBR Green I chemistry. Data are graphed as relative values, normalized 
to the 18S rRNA content of each sample, and expressed as the means ± SE (n=6 for 
untreated, n=2 for TCDD-treated). Lung Cyp1a1 RNA in untreated WT group was set as 
1.0.
Fig. 5. PhIP tissue distribution in WT mice, following oral administration of PhIP (40 
mg/kg). 30 min after PhIP treatment, mouse lung, liver, mammary gland and colon were 
collected. PhIP concentration in various tissues was analyzed by LC-MS/MS. Data are 
expressed as means ± SD (n=3).
Fig. 6. PhIP-DNA adducts in lung. Cyp1a1-null mice, Cyp1a2-null mice, and WT mice 
were treated orally with 100 μg/kg [14C]PhIP (6.3 μCi/kg). The mice were killed 18 h 
after administration, and lung DNA was isolated for PhIP-DNA adducts detection by 
accelerator mass spectrometry (AMS). PhIP-DNA adducts in WT lung were set as 1.0. 
Data are expressed as means ± SD (n=4). **P<0.01 compared with WT.
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